Introduction
Haematological malignancies belong to a heterogeneous group of haematological diseases (1) (2) . Inflammation is now recognised to be an important component in cancer prognosis, with several inflammatory markers being used to monitor disease progression and prognosis (3) (4) (5) . One of the main strategies used to treat haematological malignancies is chemotherapy. Such treatment not only aims to destroy neoplastic cells, but also affects healthy cells, such as cells of the gastrointestinal tract (6) . Adverse effects caused by antineoplastic therapy include giddiness, nausea, vomiting, mucositis, dysphagia, diaorrhea, and changes in taste and smell perception (7) . Such adverse effects are linked to metabolic and nutritional losses and a subsequent deterioration in the quality of life (7, 8) . Dietary fatty acids (FAs) have profound physiological implications (9) . Studies suggest that ingestion of n-3 polyunsaturated fatty acids (PUFAs), especially docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are found in fish oil, can be beneficial for cancer treatment by preserving nutritional status (10) , decreasing inflammatory markers (e.g. positive acute-phase proteins) (11) and increasing survival (12) . However, studies using fish oil supplementation in haematological malignancies are scarce, and there is no clear information regarding any indication to use (or not use) such a nutritional strategy in these patients.
The present study aimed to evaluate the effect of oral supplementation with 2 g day À1 fish oil (a source of EPA and DHA) for 9 weeks on nutritional parameters and inflammatory status in newly diagnosed patients with haematological malignancies starting chemotherapy. Overall survival to 465 days from the start of fish oil supplementation was a secondary outcome. We hypothesised that patients diagnosed with haematological malignancies would show a reduction in overall nutritional inflammatory risk and improved survival when ingesting fish oil.
Materials and methods

Subjects
Patients with haematological malignancies who were treated at the Ambulatory and Hematology Clinical Center of the University Hospital of Santa Catarina -Florian opolis, Santa Catarina, Brazil, from November 2012 to December 2013, participated in the present randomised clinical trial (RCT). Eligibility criteria were: age ≥18 years, histopathological diagnosis of leukaemia or lymphoma and chemotherapy treatment indication. Exclusion criteria were: being in palliative care, taking statins or antiinflammatory drugs, being allergic to fish and fish derivatives, being unable to perform oral ingestion of food, having received chemotherapy previously, being pregnant, and ingesting fish oil or other n-3 PUFA supplements in the 6 months before study initiation. A nonprobabilistic convenience sample was defined by time saturation Diagnosis and disease staging were established according to routine biopsy, immunophenotyping, cytogenetics and immunohistochemistry, as conducted by the University Hospital Pathology Division.
Study design
Eligible patients were randomly allocated into one of two groups: supplemented group (SG) and unsupplemented group (UG). Randomisation was performed using an online tool: Research Randomizer (http://www.random izer.org). Odd numbers meant that patients were allocated to SG and even numbers meant allocation to UG. The study was conducted in accordance with the Declaration of Helsinki (13) . All procedures involving human patients were approved by the Research Ethics Committee of the local Institution. All participants provided their written informed consent. The trial is registered at: www.ensaiosclinicos.gov.br, under the register RBR-7q6cqg.
The patients in the SG were instructed to ingest two capsules/day of fish oil (2 g day À1 in total) for 9 weeks.
This dose has been tested effectively in previous studies (11, 14, 15) . Subjects were instructed to ingest capsules in a dose-fractionated form, approximately 20-30 min before lunch or dinner and accompanied by liquid. During the supplementation period, supplement intake was controlled by weekly telephone calls (for nonhospitalised subjects) or daily contact in the hospital. Also, subjects were instructed to record capsules intake in a provided form. The supplementation started on the first day of the chemotherapy (T0). The UG did not receive any supplement. Personal data, lifestyle information and weight loss in the previous 6 months were obtained by interview. Clinical data (haematological malignant diagnosis, stage, other diseases and medication use) were obtained from patient records.
Dietary supplement
The fish oil supplement was in the form of gelatin capsules with 1000 mg oil/capsule (Omega 3, Phytomare; Governador Celso Ramos, SC, Brazil). The oil was extracted from salmon, mackerel and sardines. Two fish oil capsules provided a total of 71.13 kJ (17 kcal) and comprised 0.7 g of saturated fatty acids, 0.5 g of monounsaturated fatty acids, 0.8 g of polyunsaturated fatty acids and 4 mg of cholesterol. Two capsules provided a total of 610 mg of n-3 PUFAs (367 mg of EPA and 243 mg of DHA). Analysis of the fatty acid profile of the fish oil capsule, by high-performance liquid chromatography (HPLC), was conducted and returned the investigated fatty acids in the proportions (%) (16) .
Blood collection
Blood samples (30 mL) were collected after approximately 8 h of fasting at two-time points: on the day prior to the first chemotherapy (baseline) and 9 weeks later (week 9). Blood was collected into vacuum tubes (Vacutainer System; BD Biosciences, Abingdon, UK) containing lithiumheparin. Plasma was prepared and stored at À80°C until thawing for determination of the fatty acid profile. Blood was collected into separating gel tubes and serum was isolated for determination of -reactive protein (CRP) and albumin concentrations.
Determination of haemogram, albumin and C-reactive protein concentration
Haemogram parameters were obtained from whole blood using an automated method (Sysmex Xe-2100; Roche, Kobe, Japan); the values are expressed as cells mm À3 .
Albumin was quantitatively determined using an automated colorimetric method (Siemens Healthcare Diagnostics Inc., Newark, DE, USA) employing bromocresol purple as a colour reagent (17) and is expressed as g dL À1 .
Serum CRP was quantified by a nephelometric method (Siemens Dade Behring Inc., Newark, DE, EUA) (18) and is expressed as mg L À1 .
Nutritional status
The variation of weight related to the previous study period was assessed by calculating the weight loss percentage, resulting from the division between DW (i.e. the difference between usual weight and current weight) and the usual weight multiplied by 100 (19) . Several variables were assessed to evaluate nutritional status. Arm circumference (AC), mid-upper arm circumference (MUAC) and triceps skinfold (TS) (expressed in cm and mm, respectively). Mid-upper arm muscle circumference (MUAMC) was calculated according to the expression: MUAC -(p 9 TS)/10. Body mass index (BMI) was calculated by the ratio of weight (kg) to the square of the height (m). The cut-off points for classification were proposed by the World Health Organization (16, 20, 21) . Nutritional Risk Index (NRI) was calculated as: 1.519 9 serum albumin (g dL À1 ) + 41.7 9 current weight (kg)/usual weight (kg). The classification adopted was: No nutrition risk, >100; Borderline nutrition risk, 99.9-97.5; Mild nutrition risk, 83.5-97.5; and Severe nutritional risk, <83.5 (22, 23) . The CRP/albumin index was applied to categorise the inflammatory-nutritional prognosis of the patient. The classification adopted was: without risk, <0.4; low risk, 0.4-1.2; moderate risk, 1.2-2.0; and high risk, >2.0 (24) .
Plasma fatty acids profile
The plasma fatty acid profile was determined by HPLC according to the method described by Nishiyama-Naruke et al. (25) . Plasma fatty acid constituents of phospholipids, triacylglycerols, cholesterol esters and free fatty acids were extracted using chloroform : methanol (2 : 1, v/v), adapting the method described by Folch et al. (26) . Lipid extracts were suspended in methanol and the pH was adjusted to ≥12 with 5 mol L -1 NaOH. The aqueous solution was acidified with hydrochloric acid (pH ≤ 3) and subjected to a new lipid extraction using hexane, followed by evaporation in gas N 2 at 37°C. Fatty acids were derivatised with 4-bromomethyl-7-coumarin and acetonitrile as described by Abushufa et al. (27) and subsequently separated on a reversed phase analytical column (Discovery BIO Wide Pore, C8, 5 microns particles, 250 9 4.6 mm; Supelco/Sigma-Aldrich, St Louis, MO, USA). The chromatographic analysis was performed with an Alliance BIO Separation Module e2796 (Waters Corp., Milford, MA, USA). Sixteen microlitres of derivatised fatty acids were injected and then eluted by the binary gradient of acetonitrile: water from 70 : 30-90 : 10 at 0.5 mL min Waters Corp.), with excitation at 325 nm and emission at 398 nm. Chromatographic data were recorded and integrated into EMPOWER PRO, version 2.0 (Waters Corp.). The fatty acids investigated were: DHA, EPA, arachidonic, stearic, oleic, linoleic, a-linolenic, palmitic, myristic and lauric. Data are expressed as a percentage of total fatty acids.
Overall survival, hospital readmissions and number of chemotherapy sessions
Overall survival (OS) was defined as the time elapsed between baseline (the day of the first chemotherapy) and death from any cause or censored if alive at follow-up date [the follow-up was standardised to 465 days (15.5 months) after study entry]. The date of death, hospital readmissions and the number of chemotherapy sessions were recorded from patient medical records. OS curves were computed using the Kaplan-Meier method and compared using log-rank tests.
Statistical analysis
In the statistical analysis, the intake of fish oil was considered as the exposure variable. Data normality was tested by applying the Shapiro-Wilk test. A Student's unpaired t-test or a Mann-Whitney test were used to test for differences between groups at each time point. A Student's paired ttest or a Wilcoxon test for paired data were used to test the differences between time points within a study group.
All analyses were performed in STATA, version 11.0 (StataCorp, College Station, TX, USA) and images were prepared using PRISM, version 5.01 (Graphpad Inc., La Jolla, CA, USA). P < 0.05 was considered statistically significant.
Two models for statistical analyses were applied: Model 1 included all eligible patients who agreed to participate and finished the 9 weeks of follow-up; Model 2 included patients from SG who presented ≥100% increment in proportions of plasma EPA and DHA at 9 weeks compared to baseline and UG patients who did not show an increment (<50% increase) in plasma EPA and DHA at 9 weeks compared to baseline. Such a strategy was applied to reduce any potential heterogeneity related to the absorption and incorporation of fatty acids caused by the chemotherapy.
Results
Eighty-one new cases of haematological diseases were identified at University Hospital Professor Polydoro Ernani de São Thiago/Federal University of Santa Catarina between November 2012 and December 2013. Fifty patients were not eligible for participation in the study according to the inclusion/exclusion criteria. Therefore, 31 patients were invited to take part in the trial. Three patients chose not to participate. Finally, 28 patients (90.3% of the eligible patients) were randomised to two study groups (Model 1). Subsequently, according to the analysis of the plasma fatty acid profile, 14 patients were randomised to the same two study groups (Model 2), as shown in Fig. 1 . Six participants were withdrawn from the study (three per group). The reasons for withdrawal are given in Fig. 1 .
In both analysis models, plasma EPA and DHA concentrations did not change in the UG (P > 0.05) (see Supporting information, Table S1 ). In the SG, EPA and DHA increased in both analysis models. However, the increase in plasma DHA for model 1 reached a P value of 0.07, which can be interpreted as a statistical tendency (see Supporting information, Table S1 ).
Characteristics of the study participants
Baseline characteristics of the 22 randomised patients for Model 1 and the 14 patients in Model 2 did not differ between UG and SG (Table 1) . Acute leukaemia and non-Hodgkin lymphoma were the main diagnoses in patients included in both analysis models. The distribution of patients between groups according to sex was not different. The concomitant diseases presented by the patients were: osteoporosis, type 2 diabetes mellitus, hypertension, rheumatoid arthritis, depression, gastritis, gastric ulcer, hiatal hernia, oesophagitis and hypothyroidism, and hyperthyroidism. The percentage of weight loss in the last 6 months before chemotherapy was numerically higher in the UG compared to the SG and was statistically significant.
Anthropometric parameters and nutritional status
No significant changes were observed in either analysis model for weight, MUAC, TS and MUAMC (Table 2) . For Model 2, BMI was lower in SG than in UG at the end of the 9 weeks (P < 0.05). However, NRI was higher in SG than in UG using Model 2 (P < 0.05) ( Table 2) .
The CRP/albumin ratio for both models of analysis is shown in Fig. 2 . Both groups had a significant decrease in the inflammatory-nutritional risk from baseline to the ninth week (T1) for analysis model 1. UG patients changed their classification from high to the medium and low risk of complications categories. In the group ingesting fish oil, most patients were categorised as low risk or no risk after supplementation [median (interquartile range): UG = 5.1 (2.0-31.6) to 1.4 (1.0-9.0); SG = 12.6 (2.8-18.1) to 1.1 (0.9-6.8); P < 0.05]. There were no significant differences between groups when analysis model 2 was applied, in addition to the same changes as the lower risk category (Fig. 2) .
Blood, serum and plasma parameters UG showed a significant increase in red blood cell count with both analysis models (Table 3) . Haematocrit and leukocytes increased significantly after 9 weeks for model 1 (P < 0.05). These changes did not occur in the SG. Additionally, using Model 1, the SG had a significant reduction in serum levels of CRP (P < 0.05), which did not occur in patients in the UG (Table 3 ).
Overall survival of the patients who completed the study During the 9 weeks of the trial, three patients in the UG died (Fig. 1) . Patients who completed the 9 weeks of the trial were followed for additional 14 months; outcomes were survival (Fig. 3) , hospital readmissions and the number of chemotherapy cycles. No significant differences were observed in the number of hospital readmissions. However, the number of chemotherapy cycles was significantly higher in the SG independent of the model of analysis (see Supporting information, Table S2 ). During the follow-up, four patients of the UG started palliative chemotherapy treatment. In the SG, two patients relapsed after 1 year of remission and were submitted to further chemotherapy sessions (data not shown).
There were no reported deaths during the 465 days of follow-up for the patients in the SG independent of the analysis model. By contrast, the total number of reported deaths in the UG was eight when analysis Model 1 was used (log-rank P = 0.005 compared to the SG group) (Fig. 3a) . Appling Model 2 analysis, there were six reported deaths in the UG (log=rank P = 0.008 compared to the SG group) (Fig. 3b) .
Discussion
The present randomised clinical trial has shown that ingesting 2 g day À1 supplemental fish oil improved longterm survival in those patients with haematological malignancies who were receiving chemotherapy. Furthermore, patients receiving fish oil were also able to undertake a greater number of cycles of chemotherapy. Fish oil containing 367 mg of EPA and 243 mg of DHA for 9 weeks was sufficient to alter the fatty acid composition of plasma lipid constituents, leading to an approximately two-fold increment in the proportion of EPA and a 1.8-fold increase for DHA. The same finding has been reported in previous studies (14, 28, 29) . Figure 1 Flowchart of patients in the present study. Model 1 included all eligible patients who agreed to participate and finished the 9 weeks of follow-up. Model 2 included patients from SG who presented ≥100% increment in the proportion of plasma eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at 9 weeks compared to baseline and UG patients who did not show an increment (<50%) in plasma EPA and DHA at 9 weeks compared to baseline.
Studies testing the effects of EPA and DHA in patients diagnosed with haematological malignancies are scarce. One previous study was performed in early-stage chronic lymphocytic leukaemia (29) and another in acute myeloid leukaemia (30) . Both studies used fish oil as a nutritional strategy in parallel with chemotherapy. However, neither of these previous studies investigated the same outcomes as those assessed in the present study. Hence, it is difficult to compare our findings with those of these two previous studies.
In vitro and review studies have concluded that EPA and DHA can induce apoptosis in leukaemic cell lineages (32) (33) (34) (35) (36) . Furthermore, in vitro studies performed with leukaemic cell lines have shown an increment in the antineoplastic action of drugs used in chemotherapy when EPA and DHA are present in the culture medium (28, 37, 38) . Additionally, in dogs with lymphoblastic lymphoma, EPA and DHA ingestion increased survival and decreased the plasma concentration of interleukin-6 (39) . RCTs conducted in different types of cancer patients receiving chemotherapy and supplemented with n-3 PUFAs have shown the positive effects of this strategy on inflammatory and nutritional outcomes. For example, a double-blind RCT in patients with lung cancer reported increased body weight and a reduction in inflammatory indices in the group receiving fish oil containing 510 mg of EPA and 310 mg of DHA (40) . A RCT testing colorectal cancer patients found that fish oil containing 367 mg of EPA and 243 mg of DHA, given daily for 9 weeks, decreased serum levels of CRP (15) , reduced inflammatory and nutritional risk (15, 41) , and maintained or increased BMI and body weight during chemotherapy (41) . A systematic review regarding the effects of n-3 PUFA in cancer patients receiving chemotherapy concluded that the main beneficial effect of this supplementation is the preservation of body weight and body composition (10) . However, in the present study, there were no significant changes in body weight or BMI with fish oil supplementation. Nevertheless, we observed a trend increment in MUAMC in the subjects supplemented with fish oil, suggesting the preservation or a gain of lean mass. In addition, NRI was higher in patients receiving fish oil.
Studies with different cancer patients have demonstrated a decrease in inflammation after supplementation with n-3 PUFAs (42) (43) (44) (45) . These effects may be partly a result of inflammatory and immune response modulation by n-3 PUFAs because of an altered pattern of production of lipid mediators including eicosanoids, such as prostaglandins, leukotrienes, thromboxanes, resolvins (E and D) and D1 protectins (46) (47) (48) . Additionally, some anti-inflammatory effects of n-3 PUFAs appear to be exerted through the decreased activation of the pro-inflammatory transcription factor nuclear factor-kappa B and perhaps an increased activation of the anti-inflammatory transcription factor peroxisome proliferator activated receptor-c (49) (50) (51) . In the present study, chemotherapy affected the CRP/ albumin ratio. In the UG, the risk classification changed from high to moderate. However, in patients who received fish oil, the risk classification changed from high to low. This risk classification decline can be indicative of a positive effect of supplementation with fish oil. The same effect was reported previously in patients with colorectal cancer (15, 41) . Thus, the CRP/albumin ratio may be a sensitive marker of the ability of fish oil supplementation to improve the inflammatory-nutritional status in these patients. Data are presented as the mean (SD) or median (interquartile range). Model 1 included all eligible patients who agreed to participate and finished the 9 weeks of follow-up. Model 2 included patients from SG who presented ≥100% increment in the proportion of plasma eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at 9 weeks compared to baseline and UG patients who did not show an increment (<50%) in plasma EPA and DHA at 9 weeks compared to baseline. BMI, body mass index; MUAC, mid-upper arm circumference; MUAMC, mid-upper arm muscle circumference; NRI, nutritional risk SG; supplemented group; T0, data before the first session of chemotherapy (baseline); T1, data after 9 weeks of chemotherapy; TS, triceps skinfold; UG, unsupplemented group; Δ, difference between the final and initial value. Survival up to 465 days of follow-up was greater when patients ingested fish oil independent of the model of analysis. Similarly, some previous studies showed prolonged survival after n-3 PUFA supplementation in patients with pancreatic cancer (12) , advanced nonsmall cell lung cancer (52) and metastatic breast cancer (53) . The longer survival might be attributed to the effects of fish oil with respect to the nutritional-inflammatory risk. Additionally, the increment of the antineoplastic action and reduction of the toxicity of the chemotherapy (54) could explain such observations.
The data reported in the present study suggest that it will be important for future trials to perform medium-or long-term follow-up of some variables relevant to the clinical environment (e.g. survival, hospital readmissions, etc.). Furthermore, it may be possible for researchers involved in previous trials to retrospectively check clinical variables from the enrolled patients with the aim of identifying medium-or long-term changes that were not part of the original follow-up in some trials.
Studies with oral fish oil supplementation have a specific limitation: the odour and aftertaste of regular fish oil affect the performance of double-blind placebo-controlled trials. Although some studies try to minimise this limitation using deodorised fish oil capsules, in medium to low-income countries, regular fish oil is easily assessable compared to other forms available in the market. Therefore, no placebo was offered to the control group. Other limitations include the study sample, which was composed of patients with different onco-haematological diagnosis, as well as with different disease staging, chemotherapy regimes and co-morbidities. However, the cohort was a result of a careful screening according to our inclusion and exclusion criteria. We consider that our criteria were important with respect to reducing additional confounding factors. Nevertheless, despite these limitations, the data from the present study provide relevant information to guide future research regarding these health conditions. Model 1 included all eligible patients who agreed to participate and finished the 9 weeks of follow-up. Model 2 included patients from SG who presented ≥100% increment in the proportion of plasma eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at 9 weeks compared to baseline and UG patients who did not show an increment (<50%) in plasma EPA and DHA at 9 weeks compared to baseline. CRP, C-reactive protein; SG, supplemented Group; T0, data before the first session of chemotherapy (baseline); T1, data after 9 weeks of chemotherapy; UG, unsupplemented group; Δ, difference between the final and initial value. *P < 0.05. †Comparison between groups at the respective time points. ‡Comparison within the same group for different time points. † †Wilcoxon test. ‡ ‡Mann-Whitney test. §t-test for paired data. § §Student's t-test.
In conclusion, the ingestion of fish oil concomitant with chemotherapy increases long-term survival (465 days after the beginning of the chemotherapy), potentially by reducing the inflammatory-nutritional risk, in patients with haematological malignancies. Larger clinical trials focusing on these patients need to be conducted to test such findings globally. Figure 3 Overall survival (OS) was defined as the time elapsed between baseline (i.e. the day of the first chemotherapy) and death from any cause until 465 days of follow-up. OS curves according to fish oil supplementation were computed using the Kaplan-Meier method and compared using log-rank tests. (a) Model 1: US (n = 13); SG (n = 9) included all eligible patients who agreed to participate and finished the 9 weeks of follow-up. (b) Model 2: UG (n = 8); SG (n = 6) included patients from SG who presented ≥100% increment in the proportion of plasma eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at 9 weeks compared to baseline and UG patients who did not show an increment (<50%) in plasma EPA and DHA at 9 weeks compared to baseline. SG, supplemented Group; UG, unsupplemented group.
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